

Company Announcement no. 12/2008

To: OMX Nordic Exchange

Hørsholm, Denmark, March 31, 2008

LifeCycle Pharma A/S – Report Pursuant to the Danish Securities Trading Act, Section 28(a)

Hørsholm, Denmark, March 31, 2008; Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons / companies closely associated with these.

| Name | Claus Braestrup |
|-----------------------------|-------------------------------------|
| Reason for reporting | Chairman of the Board of Directors |
| Issuer and ID code/ISIN | LifeCycle Pharma A/S / DK0060048148 |
| Type of transaction | Purchase of shares |
| Date of transaction | March 28, 2008 |
| Relevant market | OMX Nordic Exchange |
| Number of traded securities | 3,000 |
| Market value | DKK 72,000 |

About LifeCycle Pharma A/S ("LCP")

LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, FenoglideTM, currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP).



For further information, please visit www.lcpharma.com.

Contact:

LifeCycle Pharma A/S Hans Christian Teisen, +45 2030 6985 SVP and CFO HCT@lcpharma.com